

Table SI. Correlation between the clinicopathological features and the protein expressions of TLR4 and MyD88.

Characteristics	N	Myd88 (n, % within factor)		χ^2	P	TLR4 (n, % within factor)		χ^2	P-value
		- (%)	+ (%)			- (%)	+ (%)		
Sex ^a									
Male	39	5 (12.8)	34 (87.2)	0.501	0.479	4 (10.3)	35 (89.7)	0.000	1.000
Female	16	4 (25.0)	12 (75.0)			2 (12.5)	14 (87.5)		
Age (years) ^a									
≤50	20	5 (25.0)	15 (75.0)	0.865	0.352	2 (10.0)	18 (90.0)	0.000	1.000
>50	35	4 (11.4)	31 (88.6)			4 (11.4)	31 (88.6)		
Natio									
Han	33	5 (15.2)	28 (84.8)	0.000	1.000	1 (3.0)	32 (97.0)	3.438	0.064
Ethnic minority	22	4 (18.2)	18 (81.8)			5 (22.7)	17 (77.3)		
Tumor stage ^a									
1-2	43	9 (20.9)	34 (79.1)	1.668	0.196	4 (9.3)	39 (90.7)	0.040	0.842
3-4	12	0 (0.0)	12 (100.0)			2 (16.7)	10 (83.3)		
Nodal status ^a									
N0	29	6 (20.7)	23 (79.3)	0.303	0.582	3 (10.3)	26 (89.7)	0.000	1.000
N1-N2	26	3 (11.5)	23 (88.5)			3 (11.5)	23 (88.5)		
Tumor site ^b									
Tongue	27	4 (14.8)	23 (85.2)	0.215	0.995	4 (14.8)	23 (85.2)	2.106	0.716
Floor of the mouth	5	1 (20.0)	4 (80.0)			0 (0.0)	5 (100.0)		
Gingiva	10	2 (20.0)	8 (80.0)			1 (10.0)	9 (90.0)		
Buccal mucosa	7	1 (14.3)	6 (85.7)			0 (0.0)	7 (100.0)		
Hard palate, Jaw bone	6	1 (16.7)	5 (83.3)			1 (16.7)	5 (83.3)		
TNM stage ^a									
I-II	22	6 (27.3)	16 (72.7)	1.998	0.157	3 (13.6)	19 (86.4)	0.008	0.930
III-IV	33	3 (9.1)	30 (90.9)			3 (9.1)	30 (90.9)		
Contralateral lymph node metastasis ^a									
No	52	9 (17.3)	43 (82.7)	0.000	1.000	6 (11.5)	46 (88.5)	0.000	1.000
Yes	3	0 (0.0)	3 (100.0)			0 (0.0)	3 (100.0)		
Pathological differentiation grade ^a									
Well-moderately	51	6 (11.8)	45 (88.2)	6.709	0.01 ^c	6 (11.8)	45 (88.2)	0.000	1.000
Poorly	4	3 (75.0)	1 (25.0)			0 (0.0)	4 (100)		
Tobacco ^a									
No	27	5 (18.5)	22 (81.5)	0.004	0.952	2 (7.4)	25 (92.6)	0.149	0.700
Yes	28	4 (14.3)	24 (85.7)			4 (14.3)	24 (85.7)		
Alcohol ^a									
No	32	4 (12.5)	28 (87.5)	0.296	0.586	2 (6.2)	30 (93.8)	0.755	0.385
Yes	23	5 (21.7)	18 (78.3)			4 (17.4)	19 (82.6)		
Diabetes ^a									
No	19	5 (26.3)	14 (73.7)	1.137	0.286	0 (0.0)	19 (100.0)	2.046	0.153
Yes	36	4 (11.1)	32 (88.9)			6 (16.7)	30 (83.3)		
Underlying disease ^a									
No	12	5 (41.7)	7 (58.3)	5.010	0.025 ^c	0 (0.0)	12 (100.0)	0.718	0.397
Yes	43	4 (9.3)	39 (90.7)			6 (14.0)	37 (86.0)		
Tumor growth time (months) ^b									
≤6	42	5 (11.9)	37 (88.1)	0.105		4 (9.5)	38 (90.5)		0.555
6-12	4	2 (50.0)	2 (50.0)			1 (25.0)	3 (75.0)		
12-18	9	2 (22.2)	7 (77.8)			1 (11.1)	8 (88.9)		
Recurrence ^a									
No	53	7 (13.2)	46 (86.8)	5.214	0.022 ^c	6 (11.3)	47 (88.7)	0.000	1.000
Yes	2	2 (100.0)	0 (0.0)			0 (0.0)	2 (100.0)		

Pearson chi-square test was used to examine the protein expressions' possible association with the pathological and clinical outcomes of the case under study. ^aP-value are from continuous correction algorithm. ^bP-value are from Fisher's exact test. ^cP<0.05 statistically was considered significant. Ethnic minority include Zhuang and MuLao. Underlying diseases mainly include diabetes hypertension, heart disease. Recurrent cases were collected until October 2020.

Table SII. Correlation between the clinicopathological features and the mRNA expressions of TLR4 and MyD88.

Characteristics	N	Myd88 (Mean ± SD)	t/F	P	TLR4 (Mean ± SD)	t/F	P-value
Sex							
Male	39	4.708±10.881	0.950	0.347	2.603±4.688	0.593	0.555
Female	16	2.071±3.018			1.883±1.826		
Age (years)							
≤50	20	5.235±13.180	0.774	0.442	2.287±4.660	-0.145	0.885
>50	35	3.201±6.327			2.450±3.750		
Natio							
Han	33	3.757±10.419	-0.176	0.861	2.564±4.023	0.381	0.705
Ethnic minority	22	4.215±7.678			2.136±4.202		
Tumor stage							
1-2	43	3.513±9.329	-0.640	0.525	2.662±4.522	1.576	0.121
3-4	12	5.474±9.644			1.430±1.274		
Nodal status							
N0	29	2.473±3.738	-1.180	0.248	2.152±4.146	-0.463	0.645
N1-N2	26	5.578±12.947			2.663±4.031		
Tumor site ^a							
Tongue(A)	27	4.421±11.372	0.247	0.910	3.018±4.285	1.220	0.314
Floor of the mouth(B)	5	2.316±3.570			0.987±0.402		
Gingiva(C)	10	3.008±3.614			1.151±1.469		
Buccal mucosa(D)	7	2.270±4.325			4.309±7.237		
Hard palate, Jaw bone(E)	6	6.635±13.998			0.664±0.689		
TNM stage							
I-II	22	2.095±4.016	-1.410	0.166	2.193±4.737	-0.296	0.769
III-IV	33	5.171±11.525			2.527±3.616		
Contralateral lymph node metastasis							
No	52	4.030±9.604	0.295	0.769	2.439±4.154	0.347	0.730
Yes	3	2.382±1.210			1.595±2.116		
Pathological differentiation grade							
Well-moderately	51	4.134±9.674	0.544	0.588	2.467±4.193	0.479	0.634
Poorly	4	1.475±1.684			1.450±1.650		
Tobacco							
No	27	4.398±11.244	0.354	0.725	2.461±3.872	0.119	0.906
Yes	28	3.499±7.242			2.329±4.308		
Alcohol							
No	32	3.935±10.653	-0.005	0.996	2.238±3.861	-0.332	0.741
Yes	23	3.948±7.374			2.610±4.406		
Diabetes							
No	19	2.257±2.762	-1.291	0.204	2.333±4.433	-0.080	0.937
Yes	36	4.829±11.332			2.425±3.918		
Underlying disease							
No	12	2.825±3.322	-0.465	0.644	3.240±5.412	0.814	0.419
Yes	43	4.252±10.435			2.157±3.645		
Tumor growth time (months) ^a							
≤6(A)	42	3.930±10.310	0.011	0.989	1.430±1.850	7.688	0.001 ^b
6-12(B)	4	3.380±1.800			2.920±2.270		
12-18(C)	9	4.220±6.590			6.650±8.150		
Recurrence							
No	53	3.994±9.511	0.215	0.830	2.456±4.126	0.584	0.561
Yes	2	2.533±2.528			0.735±0.030		

The t-test was used to examine the possible association between mRNA expressions and the pathological and clinical results of the cases being studied. ^aP-value are from single factor analysis of variance. Bonferroni correction: multiple comparison: MyD88: (Tumor site: A VS. B, P=1.000; A VS. C, P=1.000; A VS. D, P=1.000; A VS. E, P=1.000; B VS. C, P=1.000; B VS. D, P=1.000; B VS. E, P=1.000; C VS. D, P=1.000; C VS. E, P=1.000; D VS. E, P=1.000) (tumor growth time: A VS. B, P=1.000; A VS. C, P=1.000; B VS. C, P=1.000). TLR4: (Tumor site: A VS. B, P=1.000; A VS. C, P=1.000; A VS. D, P=1.000; A VS. E, P=1.000; B VS. C, P=1.000; B VS. D, P=1.000; B VS. E, P=1.000; C VS. D, P=1.000; C VS. E, P=1.000; D VS. E, P=1.000) (tumor growth time: A VS. B, P=1.000; A VS. C, P=0.001; B VS. C, P=0.281). ^bP<0.05 was considered to indicate a statistically significant difference. Ethnic minority mainly include Zhuang and MuLao. Underlying diseases mainly include diabetes hypertension, heart disease. Recurrent cases were collected until October 2020.